Oncotarget · 2015 · 90 citations · 20 references
MedicineImmunologyOncologyCancer ImmunologyMolecular OncologyTumor ImmunologyCancer BiomarkersImmuno-oncology BiomarkersLung CancerMalignant NeoplasmsPleural MalignanciesTumor-associated MacrophagesBiomarker-based Prognostic ModelsCancer-associated MacrophagesMacrophage BiomarkersMalignant Pleural EffusionPleural Effusion In MalignancyPrognostic BiomarkersTumor-associated CytokinesTumor-associated Macrophage Recruitment
// Li Yang 1,* , Fei Wang 1,2,* , Liping Wang 3 , Lan Huang 1 , Jing Wang 4 , Bin Zhang 5 and Yi Zhang 1,2,3 1 Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China 2 School of Life Sciences, Zhengzhou University, Zhengzhou, Henan Province, China 3 Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China 4 Department of Respiration, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China 5 Robert H. Lurie Comprehensive Cancer Center, Department of Medicine-Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago IL, USA * These authors contributed equally to this work Correspondence to: Yi Zhang, email: // Liping Wang, email: // Keywords : malignant pleural effusion, tumor-associated macrophages, CD163, prognostic biomarker, therapeutic effect Received : January 19, 2015 Accepted : February 13, 2015 Published : March 12, 2015 Abstract CD163+ tumor-associated macrophages (TAMs) play an important role in the progression of cancer. However, the significance of CD163+ TAMs in malignant pleural effusion (MPE) is still unclear. The aim of this study is to evaluate the prognostic value of CD163+ TAMs in MPE, and the regulatory effect of an immune adjuvant (pseudomonas aeruginosa - mannose-sensitive hemagglutinin, PA-MSHA, which is used for MPE treatment in clinic) on CD163+ TAMs in MPE. Here, we found that the percentage of CD163+ TAMs in MPE was significantly higher than that in non-malignant pleural effusion ( P <0.001). More importantly, CD163+ TAMs in MPE patients were an independent prognostic factor for progression-free survival. M2-related cytokines were highly expressed in MPE-derived CD163+ TAMs than in MPE-derived CD163- macrophages ( P <0.05). CD163+ TAMs frequency in MPE patients was obviously reduced after PA-MSHA treatment in clinic ( P <0.05). After treatment with PA-MSHA, M2 macrophages were re-educated to M1 macrophages in vitro . TLR4 blocking antibody inhibited M2 macrophages polarization to M1 macrophages induced by PA-MSHA. These findings highlight that accumulation of CD163+ TAMs in MPE caused by lung cancer is closely correlated with poor prognosis. CD163+ TAMs are associated with therapeutic effect in MPE. PA-MSHA re-educates CD163+ TAMs to M1 macrophages through TLR4-mediated pathway in MPE.
20
Junliang Ma, Lunxu Liu, Guowei Che et al. · BMC Cancer · 2010 · 439 citations · Full text
Sean K. Lau, Peiguo Chu, Lawrence M. Weiss · American Journal of Clinical Pathology · 2004 · 338 citations